glp 1 gip 1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect Frontiers | Mechanisms of action
Description
A helpful framework comes from insulin titration
However, in humans, the contribution of bile acid changes to metabolic improvements after bariatric procedures is less clear
Once T2DM or CKD has developed, the practicalities of their integration with other kidney protective drugs such as SGLT2is should be further explored
This is an impactful advancement in T2DM management, as some diabetics may be managing multiple injections per day if on insulin
Gamble JM, Chibrikov E, Midodzi WK, Twells LK, Majumdar SR
Fujino E, Cobb KW, Schoenherr J, Gouker L, Lund E
